A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

PHASE3TerminatedINTERVENTIONAL
Enrollment

645

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

September 30, 2017

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

E10030

DRUG

bevacizumab or aflibercept

Patients are randomized to receive either bevacizumab or aflibercept

DRUG

E10030 sham injection

Pressure on the eye with a syringe with no needle

Trial Locations (207)

1000

Zagreb

1076

Budapest

1083

Budapest

1106

Budapest

1133

Budapest

1145

Budapest

2000

Santa Fe

Sydney

2145

Westmead

2150

Parramatta

2640

Albury

3002

East Melbourne

4012

Debrecen

4016

Stavanger

5000

Córdoba

6720

Szeged

7621

Pécs

8036

Graz

8200

Veszprém

10021

New York

10122

Torino

10138

Tallinn

11412

Tallinn

13008

Marseille

13224

Syracuse

14620

Rochester

15122

West Mifflin

15706

A Coruña

17011

Camp Hill

19104

Philadelphia

19107

Philadelphia

20122

Milan

20132

Milan

20157

Milan

20246

Hamburg

20815

Chevy Chase

21204

Towson

21209

Baltimore

21740

Hagerstown

23235

Richmond

23462

Virginia Beach

23538

Lübeck

24105

Kiel

25606

Morgantown

27157

Winston-Salem

28803

Asheville

29169

West Columbia

29456

Ladson

30060

Marietta

30322

Atlanta

30909

Augusta

31000

Osijek

31008

Pamplona

32308

Tallahassee

32503

Pensacola

32701

Altamonte Springs

32901

Melbourne

33012

Oviedo

33100

Udine

33308

Fort Lauderdale

33410

Palm Beach Gardens

33426

Boynton Beach

33609

Tampa

33711

St. Petersburg

33770

Largo

33880

Winter Haven

33912

Fort Myers

35016

Las Palmas de Gran Canaria

35128

Padua

37000

Tours

37075

Göttingen

40138

Bologna

42001

Paducah

43212

Columbus

Fort Worth

44122

Cleveland

44124

Ferrara

44130

Cleveland

46015

Valencia

48006

Bilbao

48034

Southfield

48145

Münster

48912

Lansing

49202

Jackson

50266

West Des Moines

51000

Rijeka

52074

Aachen

55131

Mainz

55435

Minneapolis

57701

Rapid City

60126

Ancona

60452

Oak Forest

61615

Peoria

63017

Chesterfield

63110

St Louis

63128

St Louis

64239

Tel Aviv

66204

Shawnee Mission

66211

Leawood

66615

Topeka

67091

Strasbourg

67214

Wichita

68105

Omaha

69003

Lyon

69317

Lyon

70210

Kuopio

72076

Tübingen

73104

Oklahoma City

74210

Goiânia

75006

Paris

75015

Paris

75019

Paris

75093

Plano

75231

Dallas

75745

Paris

76087

Willow Park

76100

Rouen

Rehovot

76133

Karlsruhe

78233

San Antonio

78240

San Antonio

78503

McAllen

79106

Amarillo

79606

Abilene

80045

Aurora

80210

Denver

80401

Golden

80909

Colorado Springs

84107

Salt Lake City

84132

Salt Lake City

85014

Phoenix

85295

Gilbert

85704

Tucson

85710

Tucson

87109

Albuquerque

89144

Las Vegas

89502

Reno

91120

Jerusalem

91171

Trenčín

92037

La Jolla

92211

Palm Desert

92374

Redlands

92697

Irvine

92705

Santa Ana

92835

Fullerton

93003

Ventura

93720

Fresno

94010

Créteil

94040

Mountain View

94109

San Francisco

95008

Campbell

95819

Sacramento

95841

Sacramento

97210

Portland

97239

Portland

98004

Bellevue

98383

Silverdale

110231

Bogotá

3109601

Haifa

4428164

Kfar Saba

4941492

Pita Tikva

06518

Hamden

06320

New London

02111

Boston

02114

Boston

01960

Peabody

01605

Worcester

08648

Lawrenceville

B1629ODT

Buenos Aires

C1015ABO

Buenos Aires

C1112AAI

Buenos Aires

C1120AAN

Buenos Aires

01525-001

São Paulo

04023-062

São Paulo

V5Z 1E9

Vancouver

V5Z 3N9

Vancouver

R3C 1A2

Winnipeg

L4W 1W9

Mississauga

H1T 2M4

Montral

050016

Medellín

625 00

Brno

500 05

Hradec Králové

779 00

Olomouc

10 100 34

Prague

169 02

Prague

00200

Helsinki

04103

Leipzig

00133

Roma

00198

Roma

LV-1002

Riga

LV-1050

Riga

85-631

Bydgoszcz

40-594

Katowice

91-134

Lodz

50-556

Wroclaw

3000-548

Coimbra

3030-163

Coimbra

1050-085

Lisbon

1169-050

Lisbon

4200-319

Porto

2600-009

Vila Franca de Xira

975 17

Banská Bystrica

02008

Albacete

08021

Barcelona

08022

Barcelona

08035

Barcelona

08195

Barcelona

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT01940887 - A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy | Biotech Hunter | Biotech Hunter